TW202400141A - ３－（（１ｒ，３ｒ）－１－（２，６－二氟－４－（（１－（３－氟丙基）四氫吖唉－３－基）胺基）苯基）－３－甲基－１，３，４，９－四氫－２ｈ－吡啶并［３，４－ｂ］吲哚－２－基）－２，２－二氟丙－１－醇酒石酸鹽之固體形式 - Google Patents

３－（（１ｒ，３ｒ）－１－（２，６－二氟－４－（（１－（３－氟丙基）四氫吖唉－３－基）胺基）苯基）－３－甲基－１，３，４，９－四氫－２ｈ－吡啶并［３，４－ｂ］吲哚－２－基）－２，２－二氟丙－１－醇酒石酸鹽之固體形式 Download PDF

Info

Publication number
TW202400141A
TW202400141A TW112115780A TW112115780A TW202400141A TW 202400141 A TW202400141 A TW 202400141A TW 112115780 A TW112115780 A TW 112115780A TW 112115780 A TW112115780 A TW 112115780A TW 202400141 A TW202400141 A TW 202400141A
Authority
TW
Taiwan
Prior art keywords
solution
pharmaceutical composition
formula
filler
capsule
Prior art date
Application number
TW112115780A
Other languages
English (en)
Chinese (zh)
Inventor
豪 侯
蘿拉 傑爾克
麥可 甘莫洛
Original Assignee
瑞士商赫孚孟拉羅股份公司
美商建南德克公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商赫孚孟拉羅股份公司, 美商建南德克公司 filed Critical 瑞士商赫孚孟拉羅股份公司
Publication of TW202400141A publication Critical patent/TW202400141A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW112115780A 2022-04-28 2023-04-27 ３－（（１ｒ，３ｒ）－１－（２，６－二氟－４－（（１－（３－氟丙基）四氫吖唉－３－基）胺基）苯基）－３－甲基－１，３，４，９－四氫－２ｈ－吡啶并［３，４－ｂ］吲哚－２－基）－２，２－二氟丙－１－醇酒石酸鹽之固體形式 TW202400141A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22170407 2022-04-28
EP22170407.5 2022-04-28

Publications (1)

Publication Number Publication Date
TW202400141A true TW202400141A (zh) 2024-01-01

Family

ID=81392840

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112115780A TW202400141A (zh) 2022-04-28 2023-04-27 ３－（（１ｒ，３ｒ）－１－（２，６－二氟－４－（（１－（３－氟丙基）四氫吖唉－３－基）胺基）苯基）－３－甲基－１，３，４，９－四氫－２ｈ－吡啶并［３，４－ｂ］吲哚－２－基）－２，２－二氟丙－１－醇酒石酸鹽之固體形式

Country Status (11)

Country Link
US (1) US20250282775A1 (enExample)
EP (1) EP4514792A1 (enExample)
JP (1) JP2025512583A (enExample)
KR (1) KR20250006222A (enExample)
CN (1) CN119156386A (enExample)
AU (1) AU2023262166A1 (enExample)
CA (1) CA3255956A1 (enExample)
IL (1) IL316096A (enExample)
MX (1) MX2024013116A (enExample)
TW (1) TW202400141A (enExample)
WO (1) WO2023209062A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025219830A1 (en) * 2024-04-15 2025-10-23 Novartis Ag Pharmaceutical compositions of ribociclib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117865872A (zh) 2014-12-18 2024-04-12 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
TWI915239B (zh) 2018-06-21 2026-02-11 瑞士商赫孚孟拉羅股份公司 3-((1r,3r)-1-(2,6-二氟-4-((1-(3-氟丙基)氮雜環丁-3-基)胺基)苯基)-3-甲基-1,3,4,9-四氫-2h-吡啶并[3,4-b]吲哚-2-基)-2,2-二氟丙-1-醇之固體形式及用於製備包含經取代苯基或吡啶基部分之稠合三環化合物之製程，包括其使用方法

Also Published As

Publication number Publication date
AU2023262166A1 (en) 2024-10-17
CN119156386A (zh) 2024-12-17
MX2024013116A (es) 2024-11-08
IL316096A (en) 2024-12-01
WO2023209062A1 (en) 2023-11-02
EP4514792A1 (en) 2025-03-05
JP2025512583A (ja) 2025-04-17
US20250282775A1 (en) 2025-09-11
CA3255956A1 (en) 2023-11-02
KR20250006222A (ko) 2025-01-10

Similar Documents

Publication Publication Date Title
JP6259490B2 (ja) ベンダムスチンの経口投与形及びその治療的使用
JP6396980B2 (ja) ベンダムスチンの固体投与剤
WO2004054574A1 (ja) 経口固形医薬
JP2019530727A (ja) ラモトリギンを含む経口懸濁液用の粉末
TWI794214B (zh) 包含5-氯-n4-[2-(二甲基磷醯基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺之醫藥調配物
EP2514422B1 (en) Elution stabilized teneligliptin preparation
JP2025169294A (ja) カルバメート化合物を含む経口用医薬組成物及びその製造方法
EP3354283B1 (en) Pharmaceutical capsule composition comprising silodosin
KR20160104725A (ko) 비정상적 세포 성장의 치료를 위한 조성물 및 방법
EP2701689B1 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
US20250282775A1 (en) Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate
US11648242B2 (en) Pharmaceutical composition comprising pimavanserin, process of preparation and use thereof
HK40115442A (zh) 3-((1r，3r)-1-(2，6-二氟-4-((1-(3-氟丙基)氮杂环丁烷-3-基)氨基)苯基)-3-甲基-1，3，4，9-四氢-2h-吡啶并[3，4-b]吲哚-2-基)-2，2-二氟丙-1-醇酒石酸盐的固体形式
JP6669937B2 (ja) ５−ｈｔ６拮抗薬の医薬組成物
EP2677868B1 (en) Pharmaceutical compositions of maraviroc and process for the preparation thereof
US20250134820A1 (en) Pharmaceutical compositions
RU2024129716A (ru) ТВЕРДАЯ ФОРМА ТАРТРАТА 3-((1R,3R)-1-(2,6-ДИФТОР-4-((1-(3-ФТОРПРОПИЛ)АЗЕТИДИН-3- ИЛ)АМИНО)ФЕНИЛ)-3-МЕТИЛ-1,3,4,9-ТЕТРАГИДРО-2H-ПИРИДО[3,4-b]ИНДОЛ-2-ИЛ)-2,2- ДИФТОРПРОПАН-1-ОЛА
KR20230026415A (ko) 경구 제제 및 이의 용도